Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B

Fineline Cube Dec 21, 2025
Company Drug

SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target

Fineline Cube Dec 21, 2025
Company Drug

Guangdong Taienkang Secures NMPA Approval for Safinamide Generic

Fineline Cube Sep 19, 2025

Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced that the National Medical Products Administration (NMPA)...

Company Drug

Hengrui Pharma Secures Breakthrough Therapy Designation for SHR‑1501 in China

Fineline Cube Sep 19, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that its investigational injectable SHR‑1501...

Others

GE Healthcare Eyes Sale of China Unit Amid Revenue Decline

Fineline Cube Sep 19, 2025

GE Healthcare Technologies Inc. (NASDAQ: GEHC) is reportedly exploring the sale of a stake in...

Company Drug

Hengrui Pharma Secures NMPA Approval for Two Novel Immune‑Inflammatory Drugs

Fineline Cube Sep 19, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that China’s National Medical Products...

Company Deals Drug Medical Device

GenSci Secures Exclusive Rights to ALK’s House Dust Mite Allergy Therapies in China

Fineline Cube Sep 18, 2025

Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) announced a strategic partnership with ALK (ALKB:DC / OMX:...

Company Drug

Jiangsu Hengrui Secures Priority Review for Trastuzumab Rezetecan in HER2‑Positive Breast Cancer

Fineline Cube Sep 18, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products...

Company Drug

Chongqing Genrix Secures NMPA Trial Approval for GR2301 IL‑15 Antibody in Vitiligo

Fineline Cube Sep 18, 2025

Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced that the National Medical Products Administration (NMPA)...

Company Drug

Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17‑Positive Solid Tumors

Fineline Cube Sep 18, 2025

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA)...

Company Drug

Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 Phase 3 Trial

Fineline Cube Sep 18, 2025

Eli Lilly and Company (NYSE: LLY) announced positive topline results from the open‑label, randomized Phase 3...

Company Deals

Eisai China Partners with DSM‑Firmenich’s i‑Health to Bring Lactéol to Mainland China

Fineline Cube Sep 18, 2025

Eisai (TYO: 4523) China, operating through its subsidiary Eisai (Liaoning) Pharmaceutical Co., Ltd., announced a...

Company Deals

Biocytogen Eyes A‑Share Listing on Shanghai’s STAR Market to Fund Preclinical R&D Growth

Fineline Cube Sep 18, 2025

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has filed a prospectus announcing plans to seek...

Company Drug

Jiangsu Hengrui HRS‑5635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis B

Fineline Cube Sep 18, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its next‑generation small‑interfering RNA...

Company Deals

Roche Announces $2.4 B Acquisition of 89bio, Targeting Liver and Cardiometabolic Therapies

Fineline Cube Sep 18, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that it will acquire 89bio, Inc. (NASDAQ: ETNB)...

Company Drug

Eli Lilly’s Mounjaro Shows Promising Results in Children with Type 2 Diabetes

Fineline Cube Sep 18, 2025

A recent clinical study published by Eli Lilly & Co. (NYSE: LLY) demonstrates that the GLP‑1...

Company Deals

Siemens Healthineers and Stryker Forge Neurovascular Robotics Alliance

Fineline Cube Sep 18, 2025

Siemens Healthineers (ETR: SHL) and Stryker (NYSE: SYK) today announced a strategic partnership to co‑develop...

Drug Policy / Regulatory

China CDE Seeks Public Feedback on 98th Batch of Reference Standards for Generic Drugs

Fineline Cube Sep 18, 2025

The China Center for Drug Evaluation (CDE) has published a draft list of the 98th...

Company Deals

Mabwell Bioscience Teams With Aditum Bio to Launch Kalexo Bio, Inc., Targeting $1 B in Cardio siRNA Deal

Fineline Cube Sep 18, 2025

Mabwell Bioscience (SHA: 688062) announced a strategic partnership with Aditum Bio Fund 3, L.P. to form Kalexo...

Company Deals

Cook Medical & Siemens Healthineers Partner to Launch First Radiation‑Free iMRI Suite

Fineline Cube Sep 17, 2025

Cook Medical and Siemens Healthineers (ETR: SHL) today announced a strategic collaboration aimed at redefining...

Company

Eli Lilly Unveils $5 B Virginia Facility to Scale Bioconjugate & Antibody Production

Fineline Cube Sep 17, 2025

Eli Lilly (NYSE: LLY) announced plans to construct a $5 billion manufacturing complex just west of...

Company

AstraZeneca China Decentralises Medical Affairs, Signals Shift in Global Strategy

Fineline Cube Sep 17, 2025

AstraZeneca (AZ; NASDAQ: AZN) China announced a sweeping re‑organisation that removes the country‑level Head of...

Posts pagination

1 … 35 36 37 … 600

Recent updates

  • EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B
  • SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target
  • Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration
  • BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer
  • BeOne Medicines Names Dual Presidents in Leadership Overhaul
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B

Company Drug

SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Company Drug

BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.